Cell News and Research

RSS

Nanobotmodels Company offer vision of future DNA and cell-repair techniques

Developments in nanotechnology and nanorobotics are opening up the prospects for nanomedicine and regenerative medicine where informatics and DNA computing can become the catalysts enabling health care applications at sub-molecular or atomic scales. While nanomedicine promises a new exciting frontier for clinical practice and biomedical research, issues involving cost-effectiveness studies, clinical trials and toxicity assays, drug delivery methods, and the implementation of new personalized therapies still remain challenging.

18 Mar 2010

Tissue micro-processing solutions at volumes <1mL

At Analytica 2010 in Munich, Germany, Seward Ltd will demonstrate its small tissue processing solutions in Hall B2, Stand 130. This range includes the Stomacher® 80 microbag, designed specifically for use in the Stomacher 80 microBiomaster to prepare and process biological samples at volumes as low as 250µL to 5 mL.

18 Mar 2010

USPTO allows Regulus Therapeutics' claims covering methods of antagonizing miR-181a for regulating immune response

Regulus Therapeutics Inc. announced today that the United States Patent and Trademark Office (USPTO) has allowed claims in U.S. Application Serial No. 11/977,506 covering methods of antagonizing miR-181a to regulate immune response. This patent is owned by Stanford University and licensed exclusively to Regulus. miR-181a has been shown to regulate the response of immune cells, such as T lymphocytes, to specific stimuli and modulation of miR-181a could lead to a novel treatment of inflammatory disease.

18 Mar 2010

U.S. 'race gap' in the commission of violent crime has narrowed, yet persists in many cities: Study

The U.S. 'race gap' in the commission of violent crime has narrowed substantially, yet persists in many cities - with murder arrest rates for African Americans out-distancing those for whites - concludes a new 80-city study by the University of Maryland, Florida State University and the University of Oregon.

18 Mar 2010

InvestorSoup.com: CYCC's total revenues for third-quarter of 2009 decrease by 14%

InvestorSoup.com announces an investment report featuring Cyclacel Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

18 Mar 2010

Reversal of aging shown in human stem cells

A team of North American collaborators from both industrial research centers (Biotime Inc, Mandala Biosciences LLC and Sierra Sciences LLC) and academic institutes (Ontario Cancer Institute, Burnham Institute for Medical Research and The Scripps Research Institute) have demonstrated successful reversal of the developmental aging of normal human cells.

18 Mar 2010

Researchers find retinoic acid regulates SHF tissue formation

Researchers at the Keck School of Medicine of the University of Southern California have identified a key cellular mechanism that guides embryonic heart tissue formation-a process which, if disrupted, can lead to a number of common congenital heart defects.

18 Mar 2010

Combination of gemcitabine and cisplatin limits the progression of endometrial cancer: Study

Researchers from The University of Texas M. D. Anderson Cancer Center report that in a small study of women with advanced or recurrent endometrial cancer, gemcitabine and cisplatin, when used in combination, produced a response rate in fifty percent of patients.

18 Mar 2010

Bone marrow stem cells offer potential treatment for patients with peripheral arterial disease

Bone marrow stem cells suspended in X-ray-visible microbubbles dramatically improve the body's ability to build new blood vessels in the upper leg-providing a potential future treatment for those with peripheral arterial disease or PAD, say researchers at the Society of Interventional Radiology's 35th Annual Scientific Meeting in Tampa, Fla.

18 Mar 2010

LSUHSC: Differences in drug metabolism can lead to differences in the effectiveness of candidate drug

Research led by Wayne L. Backes, PhD, Professor of Pharmacology and Associate Dean for Research at LSU Health Sciences Center New Orleans School of Medicine, has found that drug metabolism depends not only upon which enzymes are present in an individual, but also how they interact, and that can be the difference in whether a drug is safely eliminated from the body or is converted into a toxic or carcinogenic byproduct.

18 Mar 2010

SBRT can improve survival rates for patients with inoperable non-small cell lung cancer

Highly-focused stereotactic body radiation therapy (SBRT) can eliminate the targeted tumor while avoiding treatment-related illness and may ultimately improve survival for patients with inoperable non-small cell lung cancer, according to early findings of a Radiation Therapy Oncology Group study published in the March 17 cancer-themed issue of the Journal of the American Medical Association.

18 Mar 2010

ForSight Labs licenses non-core ophthalmology technology from SurModics

SurModics, Inc., a leading provider of drug delivery and surface modification technologies to the healthcare industry, announced today that it has entered into an agreement with ForSight Labs, LLC to license certain non-core ophthalmology technology. The technology licensed in this agreement does not include the Company’s I-vation™ drug delivery technology. While the license agreement contains an up-front license fee, milestone payments and royalties, specific terms of the agreement were not disclosed.

18 Mar 2010

OrbusNeich's Genous Bio-engineered R stent demonstrates long term clinical efficacy

OrbusNeich today announced that 12 month follow up data from real world patients demonstrated long term clinical efficacy of the company's Genous Bio-engineered R stent.

18 Mar 2010

SBRT doubles rate of primary tumor control compared to conventional radiotherapy

Early findings suggest a radiation therapy that involves numerous highly-focused and potent radiation beams provides targeted tumor control in nearly all patients, reduces treatment-related illness, and may ultimately improve survival for patients with inoperable non-small cell lung cancer, according to a study in the March 17 issue of JAMA, a theme issue on cancer.

18 Mar 2010

Toxins released by certain microalgae can contaminate seafood and become toxic to humans

Toxins released by certain microalgae can contaminate fish and shellfish which then become toxic to humans. Researchers from CNRS and CEA have, for the first time, identified the mechanisms of action of two of these toxins.

18 Mar 2010

Scientists discover switch mechanism that controls cells' trafficking system

Scientists have identified a mechanism that switches on an extremely important process for the proper functioning and survival of our body's cells. Specifically, the fast-track transportation pathway of 'cargo' to and from the surface of the cell.

18 Mar 2010

Grass-roots initiative raises more than $20 million to advance MDA's lifesaving mission

The spirit of St. Patrick's Day is alive and well. The Muscular Dystrophy Association today announced that, with 92 percent of some 10,000 retail locations reporting, its 2010 Shamrocks Against Dystrophy fundraiser is the most successful in the event's 27 year history.

18 Mar 2010

Research shows Caspase-1 protein plays a key role in the process of inflammation and colon cancer

Every day, our gut comes in contact with bacteria, inducing an inflammatory response that is tolerated and controlled. Sometimes the control of inflammation is lost and this can lead to inflammatory bowel disease that may predispose to colon cancer.

18 Mar 2010

Novel findings point to new therapeutic approaches for common types of cancer

Increased understanding of the Skp2 gene and its relation to cellular senescence may lead to the development of novel agents that can suppress tumor development in common types of cancer, researchers from The University of Texas M. D. Anderson Cancer Center and Memorial Sloan-Kettering Cancer Center report in the journal Nature.

18 Mar 2010

New findings promise to have fundamental significance in the fight against cancer

Cells have two different protection programs to safeguard them from getting out of control under stress and from dividing without stopping and developing cancer. Until now, researchers assumed that these protective systems were prompted separately from each other.

18 Mar 2010

Cell News and Research

Nanobotmodels Company offer vision of future DNA and cell-repair techniques

Tissue micro-processing solutions at volumes <1mL

USPTO allows Regulus Therapeutics' claims covering methods of antagonizing miR-181a for regulating immune response

U.S. 'race gap' in the commission of violent crime has narrowed, yet persists in many cities: Study

InvestorSoup.com: CYCC's total revenues for third-quarter of 2009 decrease by 14%

Reversal of aging shown in human stem cells

Researchers find retinoic acid regulates SHF tissue formation

Combination of gemcitabine and cisplatin limits the progression of endometrial cancer: Study

Bone marrow stem cells offer potential treatment for patients with peripheral arterial disease

LSUHSC: Differences in drug metabolism can lead to differences in the effectiveness of candidate drug

SBRT can improve survival rates for patients with inoperable non-small cell lung cancer

ForSight Labs licenses non-core ophthalmology technology from SurModics

OrbusNeich's Genous Bio-engineered R stent demonstrates long term clinical efficacy

SBRT doubles rate of primary tumor control compared to conventional radiotherapy

Toxins released by certain microalgae can contaminate seafood and become toxic to humans

Scientists discover switch mechanism that controls cells' trafficking system

Grass-roots initiative raises more than $20 million to advance MDA's lifesaving mission

Research shows Caspase-1 protein plays a key role in the process of inflammation and colon cancer

Novel findings point to new therapeutic approaches for common types of cancer

New findings promise to have fundamental significance in the fight against cancer

How to optimize your cell line development eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo